Open AccessThe pyrazinamide susceptibility breakpoint above which combination therapy fails
Author(s) -
Tawanda Gumbo,
E. Chigutsa,
Jotam G. Pasipanodya,
Marjolein Visser,
Paul D. van Helden,
Frederick A. Sirgel,
Helen McIlleron
Publication year - 2014
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dku136
Subject(s) - pyrazinamide , ethambutol , sputum , rifampicin , medicine , tuberculosis , sputum culture , isoniazid , mycobacterium tuberculosis , antibacterial agent , microbiology and biotechnology , gastroenterology , antibiotics , biology , pathology
To identify the pyrazinamide MIC above which standard combination therapy fails.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom